Key facts
- It has raised $1.2M; the latest was Later Stage VC in Nov 2025.
- Notable investors include SOSV, IndieBio, Arben Ventures, BioTools Innovator, Grid Exponential — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ArgenTAG
- ·The full record, as it builds
Funding rounds
No funding rounds for ArgenTAG are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArgenTAG
Operator of a healthcare platform intended to decentralize next-generation genome sequencing. The company's platform combines micro-fabrication, DNA sequencing, molecular biology, and mechanical engineering that make synthetic barcodes for sequencing samples simultaneously, enabling medical professionals to analyze antibodies and perform single-cell sequencing for anyone.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 10
- Website
- argentag.com/
- Ownership
- Privately Held (backing)
ArgenTAG doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArgenTAG shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArgenTAG in its N-PORT filings yet. We sweep new filings monthly.